Morgan Stanley Amylyx Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,950,301 shares of AMLX stock, worth $24.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,950,301

Previous 486,893 300.56%

Holding current value

$24.7 Million

Previous $3.12 Million 749.49%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$6.3 - $14.9 $9.22 Million - $21.8 Million	1,463,408 Added 300.56%	1,950,301 $26.5 Million
Q2 2025 Aug 15, 2025	BUY	$3.31 - $6.5 $41,292 - $81,087	12,475 Added 2.63%	486,893 $3.12 Million
Q1 2025 May 15, 2025	BUY	$3.0 - $4.15 $30,594 - $42,321	10,198 Added 2.2%	474,418 $1.68 Million
Q4 2024 Feb 14, 2025	SELL	$2.94 - $7.03 $41,292 - $98,736	-14,045 Reduced 2.94%	464,220 $1.75 Million
Q3 2024 May 14, 2025	SELL	$1.65 - $3.24 $736,220 - $1.45 Million	-446,194 Reduced 48.27%	478,265 $1.55 Million

Q3 2024 Nov 14, 2024	SELL	$1.65 - $3.24 $736,220 - $1.45 Million	-446,194 Reduced 48.27%	478,265 $1.55 Million
Q2 2024 May 14, 2025	BUY	$1.62 - $2.71 $745,587 - $1.25 Million	460,239 Added 99.14%	924,459 $1.76 Million
Q2 2024 Oct 17, 2024	SELL	$1.62 - $2.71 $1.86 Million - $3.11 Million	-1,146,194 Reduced 55.35%	924,459 $1.76 Million
Q2 2024 Aug 14, 2024	SELL	$1.62 - $2.71 $1.86 Million - $3.11 Million	-1,146,194 Reduced 55.35%	924,459 $1.76 Million
Q1 2024 Oct 17, 2024	BUY	$2.71 - $19.57 $3.11 Million - $22.4 Million	1,146,194 Added 123.99%	2,070,653 $5.88 Million
Q1 2024 Aug 16, 2024	SELL	$2.71 - $19.57 $2.06 Million - $14.9 Million	-759,590 Reduced 26.84%	2,070,653 $5.88 Million
Q1 2024 May 15, 2024	SELL	$2.71 - $19.57 $2.06 Million - $14.9 Million	-759,590 Reduced 26.84%	2,070,653 $5.88 Million
Q4 2023 Aug 16, 2024	BUY	$12.07 - $18.46 $23 Million - $35.2 Million	1,905,784 Added 206.15%	2,830,243 $41.7 Million
Q4 2023 Feb 13, 2024	BUY	$12.07 - $18.46 $22.7 Million - $34.7 Million	1,878,124 Added 197.26%	2,830,243 $41.7 Million
Q3 2023 Nov 15, 2023	SELL	$18.08 - $23.45 $1.8 Million - $2.34 Million	-99,727 Reduced 9.48%	952,119 $17.4 Million
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $3.13 Million - $4.69 Million	149,299 Added 16.54%	1,051,846 $22.7 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $11.6 Million - $17.1 Million	418,078 Added 86.3%	902,547 $26.5 Million
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $6.41 Million - $8.46 Million	215,399 Added 80.05%	484,469 $17.9 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $3.88 Million - $6.99 Million	225,964 Added 524.21%	269,070 $7.58 Million
Q2 2022 Oct 27, 2022	BUY	$6.85 - $19.93 $5,212 - $15,166	761 Added 1.8%	43,106 $829,000
Q2 2022 Aug 15, 2022	BUY	$6.85 - $19.93 $5,212 - $15,166	761 Added 1.8%	43,106 $829,000
Q1 2022 Oct 27, 2022	SELL	$12.85 - $32.9 $9,778 - $25,036	-761 Reduced 1.77%	42,345 $544,000
Q1 2022 May 13, 2022	BUY	$12.85 - $32.9 $544,133 - $1.39 Million	42,345 New	42,345 $544,000

Others Institutions Holding AMLX

# of Institutions

183

Shares Held

94.1M

Call Options Held

421K

Put Options Held

174K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $743M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account